NVAX Oct 2024 16.000 call
| Previous close | 0.3400 |
| Open | 0.2700 |
| Bid | 0.2100 |
| Ask | 0.2600 |
| Strike | 16.00 |
| Expiry date | 2024-10-25 |
| Day's range | 0.2700 - 0.2700 |
| Contract range | N/A |
| Volume | |
| Open interest | 231 |
PR NewswireNovavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and older for the prevention of COVID-19 in the European Union (EU). This decision follows the positive opinion from the Committee for Medicinal Products fo
ZacksNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Insider MonkeyIs Novavax, Inc. (NVAX) the Best High-Flying Stock to Buy?
We recently compiled a list of the 10 High-Flying Stocks to Buy Now. In this article, we are going to take a look at where Novavax, Inc. (NASDAQ:NVAX) stands against the other high-flying stocks. The equity markets are priced for a soft landing. This means that even the fear of a mild recession might trigger a significant […]
